Jonathan Berek

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. doi request reprint Personalizing CA125 levels for ovarian cancer screening
    Oliver Dorigo
    Department of Obstetrics and Gynecology, The UCLA David Geffen School of Medicine, Los Angeles, CA, USA
    Cancer Prev Res (Phila) 4:1356-9. 2011
  2. doi request reprint Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer
    Jonathan S Berek
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Women s Cancer Center, Stanford Cancer Center, Stanford, California, USA
    Obstet Gynecol 116:733-43. 2010
  3. doi request reprint Lymph node-positive stage IIIC ovarian cancer: a separate entity?
    Jonathan S Berek
    Department of Obstetrics and Gynecology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA
    Int J Gynecol Cancer 19:S18-20. 2009
  4. doi request reprint Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer
    Jonathan Berek
    Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Clin Oncol 27:418-25. 2009
  5. doi request reprint CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer
    Jonathan S Berek
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford Cancer Center, Stanford, CA, USA
    J Immunother 31:207-14. 2008
  6. ncbi request reprint Lymphovascular and perineural invasion in the parametria: a prognostic factor for early-stage cervical cancer
    Sanaz Memarzadeh
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California 90095 1740, USA
    Obstet Gynecol 102:612-9. 2003
  7. ncbi request reprint Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women
    Mallory Zhang
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford Cancer Center, 875 Blake Wilbur Drive, MC 5827, Stanford, CA 94305, USA
    Gynecol Oncol 104:396-400. 2007
  8. ncbi request reprint Association of lymphadenectomy and survival in stage I ovarian cancer patients
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA 94305, USA
    Obstet Gynecol 109:12-9. 2007
  9. ncbi request reprint Patterns and progress in ovarian cancer over 14 years
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford Cancer Center, Stanford, California 94305, USA
    Obstet Gynecol 108:521-8. 2006
  10. doi request reprint Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths
    Stefanie M Ueda
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, UCSF, School of Medicine and Comprehensive Cancer Center, San Francisco, CA 94143 1702, USA
    Am J Obstet Gynecol 198:218.e1-6. 2008

Research Grants

Collaborators

Detail Information

Publications35

  1. doi request reprint Personalizing CA125 levels for ovarian cancer screening
    Oliver Dorigo
    Department of Obstetrics and Gynecology, The UCLA David Geffen School of Medicine, Los Angeles, CA, USA
    Cancer Prev Res (Phila) 4:1356-9. 2011
    ..The data suggest that CA125 cutoff points might have to be stratified for subgroups of patients to reduce false-positive results. These intriguing observations will need to be validated in future screening trials for ovarian cancer...
  2. doi request reprint Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer
    Jonathan S Berek
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Women s Cancer Center, Stanford Cancer Center, Stanford, California, USA
    Obstet Gynecol 116:733-43. 2010
    ..Conversely, women at high risk of ovarian cancer should undergo risk-reducing bilateral salpingo-oophorectomy...
  3. doi request reprint Lymph node-positive stage IIIC ovarian cancer: a separate entity?
    Jonathan S Berek
    Department of Obstetrics and Gynecology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA
    Int J Gynecol Cancer 19:S18-20. 2009
    ..Patients undergoing cytoreductive surgery for advanced-stage ovarian cancer undergo concomitant retroperitoneal lymphadenectomy in an effort to improve their survival...
  4. doi request reprint Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer
    Jonathan Berek
    Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Clin Oncol 27:418-25. 2009
    ....
  5. doi request reprint CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5-year follow-up survey to a randomized placebo-controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer
    Jonathan S Berek
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford Cancer Center, Stanford, CA, USA
    J Immunother 31:207-14. 2008
    ..Velocity of CA125 rise at relapse is a highly significant predictor of survival after relapse...
  6. ncbi request reprint Lymphovascular and perineural invasion in the parametria: a prognostic factor for early-stage cervical cancer
    Sanaz Memarzadeh
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, California 90095 1740, USA
    Obstet Gynecol 102:612-9. 2003
    ..To estimate the impact of parametrial lymphovascular and perineural involvement on nodal metastasis and failure pattern of women with early-stage, surgically treated cervical cancer...
  7. ncbi request reprint Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--an analysis of 376 women
    Mallory Zhang
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford Cancer Center, 875 Blake Wilbur Drive, MC 5827, Stanford, CA 94305, USA
    Gynecol Oncol 104:396-400. 2007
    ..To evaluate prognostic factors that impact on the survival of women with ovarian sex cord stromal tumors (SCST)...
  8. ncbi request reprint Association of lymphadenectomy and survival in stage I ovarian cancer patients
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University School of Medicine, Stanford, CA 94305, USA
    Obstet Gynecol 109:12-9. 2007
    ..To estimate the survival impact of lymphadenectomy in women diagnosed with clinical stage I ovarian cancer...
  9. ncbi request reprint Patterns and progress in ovarian cancer over 14 years
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford Cancer Center, Stanford, California 94305, USA
    Obstet Gynecol 108:521-8. 2006
    ..To estimate the change in survival rates of women with ovarian cancer during the past 14 years...
  10. doi request reprint Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths
    Stefanie M Ueda
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, UCSF, School of Medicine and Comprehensive Cancer Center, San Francisco, CA 94143 1702, USA
    Am J Obstet Gynecol 198:218.e1-6. 2008
    ..The purpose of this study was to determine factors responsible for the increasing number of deaths from corpus cancer over three time periods...
  11. ncbi request reprint Vulvar melanoma: a multivariable analysis of 644 patients
    Valerie E Sugiyama
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, UCSF Comprehensive Cancer Center, 1600 Divisadero Street, San Francisco, CA, USA
    Obstet Gynecol 110:296-301. 2007
    ..To determine the prognostic factors associated with the survival of vulvar melanoma patients...
  12. ncbi request reprint Influence of the gynecologic oncologist on the survival of ovarian cancer patients
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics, University of California, San Francisco School of Medicine, San Francisco Comprehensive Cancer Center, San Francisco, California 94143 1702, USA
    Obstet Gynecol 109:1342-50. 2007
    ..To estimate the influence of gynecologic oncologists on the treatment and outcome of patients with ovarian cancer...
  13. ncbi request reprint Prognostic factors for uterine cancer in reproductive-aged women
    Nita Karnik Lee
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California 94143, USA
    Obstet Gynecol 109:655-62. 2007
    ..To determine the prognostic factors that influence the survival of younger women diagnosed with uterine cancer...
  14. ncbi request reprint Biologic and immunologic therapies for ovarian cancer
    Jonathan S Berek
    Division of Gynecologic Oncology, David Geffen School of Medicine at University of California Los Angeles, UCLA Center for the Health Sciences, Los Angeles, CA 90095 1740, USA
    J Clin Oncol 21:168s-174s. 2003
    ..A phase III study of interferon gamma in combination with first-line chemotherapy is currently ongoing...
  15. ncbi request reprint The benefit of adjuvant radiation therapy in single-node-positive squamous cell vulvar carcinoma
    Anand Parthasarathy
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford Cancer Center, 875 Blake Wilbur Drive, MC 5827, Stanford, CA 94305, USA
    Gynecol Oncol 103:1095-9. 2006
    ..To determine if adjuvant radiotherapy improves the survival of women with invasive squamous cell carcinoma of the vulva involving one inguinal node...
  16. ncbi request reprint Ovarian conservation at the time of hysterectomy for benign disease
    William H Parker
    UCLA School of Medicine, Los Angeles, California, USA
    Clin Obstet Gynecol 50:354-61. 2007
    ..Therefore, the decision to perform prophylactic oophorectomy should be approached with great caution for the majority of women who are at low risk of developing ovarian cancer...
  17. ncbi request reprint Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial
    Bradley J Monk
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive, Building 23, Room 107, Orange, CA 92868, USA
    Gynecol Oncol 96:721-8. 2005
    ....
  18. doi request reprint Prognostic factors and risk of extrauterine metastases in 3867 women with grade 1 endometrioid corpus cancer
    John K Chan
    Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Services, University of California, San Francisco School of Medicine, Helen Diller Family Comprehensive Cancer Center, 94143 1702, USA
    Am J Obstet Gynecol 198:216.e1-5. 2008
    ..The purpose of this study was to evaluate the role of surgical staging in patients with grade 1 endometrioid uterine cancer...
  19. ncbi request reprint Elective oophorectomy in the gynecological patient: when is it desirable?
    William H Parker
    UCLA School of Medicine, Los Angeles, California, USA
    Curr Opin Obstet Gynecol 19:350-4. 2007
    ..Oophorectomy is electively performed in approximately 300,000 US women per year who are having hysterectomy for benign disease...
  20. ncbi request reprint Ovarian conservation at the time of hysterectomy for benign disease
    William H Parker
    The David Geffen School of Medicine, University of California, Los Angeles, California, USA
    Obstet Gynecol 106:219-26. 2005
    ..Prophylactic oophorectomy is often recommended concurrent with hysterectomy for benign disease. The optimal age for this recommendation in women at average risk for ovarian cancer has not been determined...
  21. ncbi request reprint Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer
    Jonathan S Berek
    David Geffen School of Medicine at UCLA, Division of Gynecologic Oncology, University of California at Los Angeles, CA 90095 1740, USA
    J Clin Oncol 22:3507-16. 2004
    ..To assess oregovomab as consolidation treatment of advanced ovarian cancer and refine the immunotherapeutic strategy for subsequent study...
  22. doi request reprint HER-2/neu targeting for recurrent vulvar Paget's disease A case report and literature review
    Amer Karam
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Gynecol Oncol 111:568-71. 2008
    ..The treatment of Paget's disease of the vulva particularly for recurrences can be challenging. Overexpression of the HER-2/neu protein has been found in about 30% of vulvar Paget's cases therefore presenting a potential therapeutic target...
  23. ncbi request reprint Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA
    Jonathan S Berek
    Division of Gynecologic Oncology, David Geffen School of Medicine, University of California Los Angeles, UCLA Center for the Health Sciences 24 127, 10833 LeConte Avenue, Los Angeles, CA 90095 1740, USA
    Gynecol Oncol 99:153-9. 2005
    ..To retrospectively assess the outcome of patients undergoing pelvic exenteration for recurrent or persistence gynecologic malignancy and the clinical features associated with outcome and survival...
  24. ncbi request reprint Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy
    Mory Nouriani
    Division of Gynecologic Oncology, University of Southern California Keck School of Medicine, Los Angeles, California 90033, USA
    Clin Cancer Res 10:2681-6. 2004
    ..We hypothesized that this test, if added to second-look procedure protocols, could help determine whether residual disease is present or not in patients who have completed their adjuvant chemotherapy for ovarian carcinoma...
  25. ncbi request reprint Intraperitoneal chemotherapy for ovarian cancer
    Chad A Hamilton
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford Cancer Center, Stanford University School of Medicine, Stanford, California 94305, USA
    Curr Opin Oncol 18:507-15. 2006
    ..This review explores the background and pharmacokinetic principles of intraperitoneal chemotherapy, the recent evidence supporting an intraperitoneal approach, and some of the logistical and technical challenges involved...
  26. ncbi request reprint Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab
    Jonathan S Berek
    David Geffen School of Medicine at UCLA, 24 137 UCLA Center for the Health Sciences, 10833 Le Conte Avenue, Los Angeles, CA 90095 1740, USA
    Expert Opin Biol Ther 4:1159-65. 2004
    ..Additional studies of antigen processing and combination chemo-immunotherapy are ongoing. The treatment shows promise as a potential new addition to the standard care of ovarian cancer...
  27. ncbi request reprint Lymphadenectomy in endometrioid uterine cancer staging: how many lymph nodes are enough? A study of 11,443 patients
    John K Chan
    Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California at San Francisco School of Medicine, University of California, San Francisco Comprehensive Cancer Center, California 94143 1702, USA
    Cancer 109:2454-60. 2007
    ....
  28. ncbi request reprint Cervical cancer: an opportunity to prevent and cure
    Jonathan S Berek
    Cancer J 9:325-6. 2003
  29. ncbi request reprint Progress in the management of gynecologic cancer: consensus summary statement
    Stephen A Cannistra
    Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
    J Clin Oncol 21:129s-132s. 2003
  30. ncbi request reprint Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007
    Alan Ashworth
    Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
    Gynecol Oncol 108:652-7. 2008
    ..As ovarian cancer becomes a chronic disease, greater emphasis will be placed on the challenges facing survivors...
  31. ncbi request reprint Monoclonal antibody therapy of ovarian cancer
    Christopher F Nicodemus
    Unither Pharmaceuticals, Inc, 15 Walnut Street, Suite 300, Wellesley Hills, MA 02481 2101, USA
    Expert Rev Anticancer Ther 5:87-96. 2005
    ..These antibodies could complement novel small molecules that are also in development...
  32. ncbi request reprint Elective oophorectomy for benign gynecological disorders
    Donna Shoupe
    Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA
    Menopause 14:580-5. 2007
    ..To review the risks and benefits of elective oophorectomy and to make a clinical recommendation for an appropriate age when benefits of this procedure outweigh the risks...
  33. ncbi request reprint CA125: megadaltons of novel opportunities
    Oliver Dorigo
    Gynecol Oncol 104:505-7. 2007
  34. ncbi request reprint Surgery for ovarian cancer: how to improve survival
    Robert E Bristow
    Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    Lancet 367:1558-60. 2006
  35. ncbi request reprint Specific keynote: immunological therapy for ovarian cancer
    Jonathan S Berek
    David Geffen School of Medicine, University of California at Los Angeles, USA
    Gynecol Oncol 88:S105-9; discussion S110-3. 2003

Research Grants2

  1. MENTORING & ADVANCED RESEARCH TRAINING FOR WRHR SCHOLARS
    Jonathan Berek; Fiscal Year: 2007
    ..This cadre of Scholars will be among future leaders in women's reproductive health research in the United States. ..